Table 2 Change in clinical symptoms and inflammatory markers over 60 months based on the original allocation to vitamin D or placebo group in the VIDEO trial
Placebo | Vitamin D | Between-group change | |||
|---|---|---|---|---|---|
n | Change | n | Change | ||
WOMAC pain | 81 | − 25 (− 44.5, − 5.4) | 91 | − 26.3 (− 44.7, − 7.9) | − 1.3 (− 28.4, 25.8) |
No surgery | 66 | − 16.6 (− 37.3, 4.1) | 75 | − 34.5 (− 53.9, − 15.2) | − 17.9 (− 46.6, 10.8) |
WOMAC function | 81 | − 67.9 (− 126.4, − 9.4) | 91 | − 88.6 (− 143.6, − 33.5) | − 20.7 (− 101.6, 60.3) |
No surgery | 66 | − 34.6 (− 95, 25.9) | 75 | − 118.3 (− 174.7, − 61.8) | − 83.7 (− 167.3, 0) |
WOMAC stiffness | 81 | − 10.2 (− 18.9, − 1.4) | 91 | − 14 (− 22.2, − 5.8) | − 3.9 (− 15.9, 8.2) |
No surgery | 66 | − 5.5 (− 14.7, 3.6) | 75 | − 17.3 (− 25.8, − 8.8) | − 11.8 (− 24.4, 0.9) |
Study knee VAS pain | 81 | − 13.1 (− 18.7, − 7.5) | 92 | − 14.9 (− 20.2, − 9.7) | − 1.9 (− 9.6, 5.9) |
No surgery | 66 | − 11.2 (− 17.3, − 5.1) | 76 | − 17 (− 22.7, − 11.3) | − 5.8 (− 14.3, 2.6) |
Utility | 81 | − 0.025 (− 0.054, 0.005) | 90 | − 0.035 (− 0.063, − 0.007) | − 0.01 (− 0.051, 0.031) |
No surgery | 66 | − 0.037 (− 0.07, − 0.005) | 74 | − 0.024 (− 0.054, 0.007) | 0.014 (− 0.031, 0.058) |
PHQ9 | 80 | 0.2 (− 0.4, 0.9) | 92 | − 0.5 (− 1.1, 0.1) | − 0.8 (− 1.7, 0.2) |
No surgery | 65 | 0.8 (0, 1.5) | 76 | − 0.5 (− 1.2, 0.2) | − 1.3 (− 2.3, − 0.2) |
IL6 | 59 | − 1.9 (− 6.5, 2.7) | 80 | − 7.2 (− 11.3, − 3.1) | − 5.3 (− 11.5, 0.9) |
No surgery | 48 | − 1.7 (− 7.3, 3.8) | 68 | − 8.1 (− 13.1, − 3.1) | − 6.4 (− 13.8, 1.1) |
hs-CRP | 59 | − 0.2 (− 0.8, 0.3) | 80 | − 0.1 (− 0.6, 0.3) | 0.1 (− 0.7, 0.8) |
No surgery | 48 | − 0.1 (− 0.7, 0.5) | 68 | − 0.1 (− 0.7, 0.4) | 0 (− 0.8, 0.8) |